We demonstrated that perturbations of CLR expression profiles could be triggered directly by melanoma cells but also indirectly through melanoma-derived supernatants, suggesting that melanoma tumor cells displayed and released glycans that may interact with DCs through CLR molecules. This evidence concerns the gene DCLK3 and neoplasm.